Abstract 208P
Background
Germ cell tumours of testis is the most common cancer in young men in the western world. India has the lowest incidence globally and hence Indian data is sparse. We report the outcomes of patients with non-seminomatous germ cell tumours of testis treated at a tertiary cancer centre in South India over a period of ten years.
Methods
Patients with a histopathological diagnosis of non-seminomatous germ cell tumours of testis from Jan 1, 2006 to Dec 31, 2016 were included in the study. Patient demographics, tumour characteristics and treatment details were retrieved from case records. Kaplan-Meier method was used to estimate progression-free survival and overall survival. Cox regression model was used to analyse the prognostic factors.
Results
One hundred and nineteen patients with non-seminomatous germ cell tumours of testis of testis were included in the study. The median follow-up was 81 months. The estimated four-year overall survival and progression-free survival was 87.1% and 84.5% respectively. The four-year overall survival for good, intermediate and poor-risk groups was 93.6%,87.5% and for 52.6% respectively. The progression-free survival at four years was 91.4%, 87.8% and 47.4% for good, intermediate and poor-risk groups respectively. The presence of non-pulmonary visceral metastasis and biochemical response after chemotherapy were significant factors for overall survival and progression free survival in multivariate cox proportional hazards regression.
Conclusions
The survival figures are comparable to the rest of the world except in the poor prognostic risk group. The inferior survival noticed in this group of patients may be due to the lack of good salvage procedures. High dose chemotherapy with stem cell support may be considered more often for this group of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
313P - Diagnostic value of micro RNA (miRNA) in renal cell cancer: A meta-analysis and systemic review
Presenter: Jestoni Aranilla
Session: e-Poster Display Session
314P - Comprehensive microbial signatures and genomic profiling in tumour samples using next generation sequencing
Presenter: Mei Qi Yee
Session: e-Poster Display Session
315P - High-penetrance breast and/or ovarian cancer susceptibility genes in Filipinos
Presenter: Frances Victoria Que
Session: e-Poster Display Session
316P - Implementation of Vela Analytics to accelerate comprehensive interpretation and reporting of next-generation sequencing-based oncology testing in clinical diagnostic laboratories
Presenter: Yingnan Yu
Session: e-Poster Display Session
317P - Genomic profiling and molecular pathology of Chinese glioma patients
Presenter: yuanli Zhao
Session: e-Poster Display Session
320P - Psychometric interplay of the perception of the real-life impact of COVID-19 pandemic: A cross-sectional survey of patients with newly diagnosed malignancies
Presenter: Kelvin Bao
Session: e-Poster Display Session
321P - Impact of COVID-19 and lockdown on adherence to treatment schedule among cancer patients
Presenter: Krishnamani Kalpathi
Session: e-Poster Display Session
322P - Challenged faced by cancer patients during the COVID-19 pandemic
Presenter: mithra Krishnamani
Session: e-Poster Display Session
323P - Oncology care in the Republic of Kazakhstan during COVID-19
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
324P - COVID era: Perception of oncologists from a developing nation
Presenter: Rakesh Roy
Session: e-Poster Display Session